Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...

Prof Tony Mok speaks to ecancer at the European Lung Cancer Congress 2019 about the Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). Prof Mok emphasises that the importance of KEYNOTE-42 is that it will support the efficacy of patients over 50% PD-L1 expression, and also to see if there is an over-survival benefit at the 1% PD-L1 expression cutoff. He outlines the data so far, and what this means for the use of single agent pembrolizumab for the 1-49% subgroup as a first line therapy, and the small group of patients that might be applicable for this treatment as opposed to the alternative KEYNOTE-189 regimen. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php